Literature DB >> 7822726

Neuropsychological profile of children with neurofibromatosis, brain tumor, or both.

B D Moore1, J L Ater, M N Needle, J Slopis, D R Copeland.   

Abstract

Neurofibromatosis type 1, a common autosomal dominant genetic disorder, is associated with numerous physical and medical anomalies as well as an increased incidence of learning disability. Tumors of the central nervous system have been estimated to occur in 15%, but their contribution to neuropsychological status is unknown. This study examines the relative contribution of neurofibromatosis and brain tumor to the cognitive profile of children with neurofibromatosis. A comprehensive battery of neuropsychological and behavioral tests was administered to a group of 65 children with neurofibromatosis type 1. Fourteen were then matched on demographic variables with two other groups of children who had either a brain tumor in addition to neurofibromatosis or a brain tumor alone. The two brain tumor groups were also matched on tumor type, location, and therapy. Mean scores of the neurofibromatosis-brain tumor group were generally the lowest of the three groups; those of the brain tumor group were highest, and performance of the neurofibromatosis group was generally between the other two groups. These results suggest that neurofibromatosis is, by itself, associated with significant cognitive morbidity, but that the severity of the problems is increased somewhat if a brain tumor is also present.

Entities:  

Mesh:

Year:  1994        PMID: 7822726     DOI: 10.1177/088307389400900406

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  16 in total

1.  A child with axillary freckling and café au lait spots.

Authors:  Stephen Wainer
Journal:  CMAJ       Date:  2002-08-06       Impact factor: 8.262

2.  Neurocognitive deficits in children with neurofibromatosis type 1.

Authors:  Roger J Packer
Journal:  Curr Neurol Neurosci Rep       Date:  2006-03       Impact factor: 5.081

3.  Paired associate learning in children with neurofibromatosis type 1: implications for clinical trials.

Authors:  Jonathan M Payne; Belinda Barton; E Arthur Shores; Kathryn N North
Journal:  J Neurol       Date:  2012-08-09       Impact factor: 4.849

4.  Psychological aspects of von Recklinghausen neurofibromatosis (NF1)

Authors:  K N North
Journal:  J Med Genet       Date:  1996-09       Impact factor: 6.318

5.  Cognitive profile of children with neurofibromatosis and reading disabilities.

Authors:  Laurie E Cutting; Terry M Levine
Journal:  Child Neuropsychol       Date:  2010       Impact factor: 2.500

6.  Optic pathway gliomas in adolescence--time to challenge treatment choices?

Authors:  Amy Lee Chong; Jason D Pole; Katrin Scheinemann; Juliette Hukin; Uri Tabori; Annie Huang; Eric Bouffet; Ute Bartels
Journal:  Neuro Oncol       Date:  2013-01-07       Impact factor: 12.300

Review 7.  Neurocognitive dysfunction in children with neurofibromatosis type 1.

Authors:  Tena L Rosser; Roger J Packer
Journal:  Curr Neurol Neurosci Rep       Date:  2003-03       Impact factor: 5.081

Review 8.  Psychological aspects of von Recklinghausen neurofibromatosis (NF1)

Authors:  S E Mouridsen; S A Sørensen
Journal:  J Med Genet       Date:  1995-12       Impact factor: 6.318

9.  Multivariate pattern analysis reveals subtle brain anomalies relevant to the cognitive phenotype in neurofibromatosis type 1.

Authors:  João V Duarte; Maria J Ribeiro; Inês R Violante; Gil Cunha; Eduardo Silva; Miguel Castelo-Branco
Journal:  Hum Brain Mapp       Date:  2012-09-11       Impact factor: 5.038

10.  Nonrandomized comparison of neurofibromatosis type 1 and non-neurofibromatosis type 1 children who received carboplatin and vincristine for progressive low-grade glioma: A report from the Children's Oncology Group.

Authors:  Joann L Ater; Caihong Xia; Claire M Mazewski; Timothy N Booth; David R Freyer; Roger J Packer; Richard Sposto; Gilbert Vezina; Ian F Pollack
Journal:  Cancer       Date:  2016-04-08       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.